🩺 Anterior Segment OCT Angle-Closure Glaucoma Risk

Swept-Source Anterior Segment OCT — Non-Contact Cross-Sectional Imaging of the Iridocorneal Angle

Anterior segment OCT (AS-OCT) devices such as the CASIA2 (Tomey) and Visante/Cirrus AS-OCT (Zeiss) use swept-source or spectral-domain interferometry at long wavelengths (1310nm for CASIA2, penetrating the sclera and iris pigment epithelium far better than visible light) to generate high-resolution cross-sectional images of the anterior chamber angle in a fraction of a second — without ever touching the cornea. This is a categorically different examination from gonioscopy, and it converts angle assessment from a subjective, operator-dependent visual grading exercise into a quantitative, reproducible, image-based measurement.

• 1310 nm: Wavelength (CASIA2) (swept-source, deep tissue penetration)
• 50,000/s: A-scan speed (axial resolution ≈10 µm)
• <2.4 s: Full 360° acquisition (128 radial B-scans, one sweep)
• None: Corneal contact required (vs. goniolens + topical anesthetic)

Why AS-OCT displaced gonioscopy as the quantitative reference standard

Gonioscopy — indentation or Goldmann/Zeiss direct visualization through a contact goniolens — has been the clinical gold standard for angle assessment for decades, and remains necessary to see peripheral anterior synechiae and angle pigmentation directly. But it has structural limitations AS-OCT was built to solve:

Gonioscopy limitations: • Requires corneal contact + topical anesthesia (patient-dependent tolerance, corneal epithelial risk) • Grading is subjective: Shaffer system (0–4) or Spaeth system depend on examiner experience and ambient light control • Indentation gonioscopy itself can mechanically force open an appositionally closed angle, causing false-negative (or artifactually reassuring) grading • Cannot be performed reliably in an acute, painful, photophobic eye with corneal edema • Documentation is a hand-drawn diagram, not a quantitative, reproducible image

AS-OCT advantages: • Zero contact: the patient looks into the device; scan acquired in <1 second per meridian, full 360° map in ~2.4 seconds (CASIA2, 128 radial B-scans) • Fully quantitative: angle opening distance, area, and iris curvature reported in microns/mm² rather than a 0–4 ordinal grade • Operator-independent: image acquisition requires minimal skill; measurement algorithms are automated and reproducible between visits and between examiners • Dynamic testing: identical protocol repeatable in dark and light conditions to capture physiologic pupil-driven angle change — something gonioscopy cannot standardize • Also images the cornea (pachymetry, curvature for refractive/keratoconus screening) and captures anterior chamber depth and lens vault in the same sweep

AS-OCT does not fully replace gonioscopy — it cannot directly visualize peripheral anterior synechiae extent, angle pigmentation (Sampaolesi line), or blood vessels the way direct visualization can, and dense iris pigment or media opacity can attenuate the OCT signal near the angle recess. Ultrasound biomicroscopy (UBM), which requires an immersion contact technique but penetrates behind the iris, remains the complementary tool for visualizing the ciliary body directly — the anatomic structure most relevant to plateau iris. In practice, AS-OCT is used as the first-line, non-contact screening and quantification tool, with gonioscopy and UBM reserved for cases needing synechiae mapping or ciliary body visualization.

Three Mechanisms of Angle Closure — Pupillary Block, Plateau Iris, and Phacomorphic Crowding

Angle closure is not one disease — it is a final common anatomic endpoint (iris apposition to the trabecular meshwork) reached by at least three distinct mechanisms, and correctly identifying which one (or which combination) is operating in a given eye determines whether laser iridotomy alone will fix the problem, or whether iridoplasty or lens extraction is required. AS-OCT, by directly visualizing iris curvature, lens position, and the angle recess, is central to distinguishing between them.

• ~70–75%: Pupillary block (of angle-closure eyes, pure or predominant)
• ~10–15%: Plateau iris (persists after iridotomy in this subset)
• Rises with age: Phacomorphic component (lens thickens ~20 µm/year after age 40)
• 4–6 mm: Pupil diameter of peak risk (mid-dilation, maximal iris-lens contact)

Distinguishing pupillary block, plateau iris, and lens-induced (phacomorphic) closure

Relative pupillary block: • The most common mechanism (~70–75% of cases). Physiologic contact between the iris pupillary margin and the anterior lens surface creates resistance to aqueous flow from the posterior chamber to the anterior chamber. • A pressure gradient builds up posterior to the iris, bowing the peripheral iris forward (anterior convexity, "iris bombé" in severe cases) into the angle recess. • Risk peaks at mid-dilation (pupil 4–6mm) — the pupil is open enough to lose the sphincter's flattening tone, but not dilated enough to pull the peripheral iris fully out of the angle. This is why acute angle-closure attacks are classically precipitated by dim light, emotional stress, or anticholinergic/sympathomimetic drugs. • Definitive treatment: laser peripheral iridotomy (LPI) creates an alternate flow path directly from posterior to anterior chamber, eliminating the pressure gradient and resolving the bowing — effective in >90% of eyes where pupillary block is the sole mechanism.

Plateau iris configuration / syndrome: • The ciliary processes are anteriorly rotated or positioned directly against the peripheral iris, mechanically pushing it into the angle independent of any pupillary pressure gradient. • Central anterior chamber depth is often normal (distinguishing it from phacomorphic closure), and the iris plane is characteristically flat centrally with an abrupt anterior "hump" at the far periphery on AS-OCT — a shape gonioscopy alone cannot reliably characterize. • Plateau iris syndrome is diagnosed when an occludable angle persists after a demonstrably patent LPI has eliminated the pupillary block component — proof the peripheral crowding is ciliary-body driven, not pressure driven. • Confirmed on UBM (best for direct ciliary body visualization) or inferred on AS-OCT by persistent angle apposition post-iridotomy with a flat central iris.

Phacomorphic (lens-induced) angle closure: • The crystalline lens grows throughout life — axial thickness increases roughly 20 microns per year after age 40 — and continued anterior lens surface displacement pushes the entire iris-lens diaphragm forward, shallowing the anterior chamber and crowding the angle diffusely, not just at the pupil margin. • Disproportionately affects hyperopic eyes (short axial length, typically <22mm, with an inherently shallow anterior chamber to begin with) and eyes with intumescent (swollen) cataracts, where the effect is acute and severe. • Lens vault (perpendicular distance from the anterior lens pole to a line joining the two scleral spurs) is the AS-OCT parameter that best captures this mechanism; values above roughly 600 µm correlate strongly with a phacomorphic contribution. • Because the etiology is a physically larger lens rather than a pressure gradient, LPI alone provides only partial relief; clear lens extraction is frequently required and, per the EAGLE trial (Azuara-Blanco et al., Lancet 2016), is now favored as first-line treatment over LPI in phacomorphic and higher-pressure PAC/PACG eyes.

Most real eyes combine mechanisms in varying proportion — a patient may have primarily pupillary block with a smaller plateau or phacomorphic contribution — which is exactly why quantitative, repeatable AS-OCT imaging before and after LPI, rather than a single static gonioscopy grade, is required to plan treatment correctly.

Quantitative Angle Metrics — AOD750, TISA750, ARA, Lens Vault, and Iris Curvature

AS-OCT software automatically identifies the scleral spur — the point where the scleral inner surface changes angulation, marking the posterior extent of the trabecular meshwork — and uses it as the fixed anatomic landmark from which every downstream angle measurement is calculated. This single reproducible reference point is what allows AS-OCT metrics to be compared across visits, across eyes, and across populations in a way that Shaffer-grade gonioscopy never could.

• 0.35–0.70 mm: AOD750 (normal) (narrow/occludable if <0.19 mm)
• 0.10–0.20 mm²: TISA750 (normal) (trabecular-iris space area)
• >600 µm: Lens vault (elevated) (phacomorphic contribution likely)
• AOD500 <200 µm: Occludable-angle cutoff (or Shaffer grade ≤2 equivalent)

From scleral spur to angle opening distance, TISA, ARA, and lens vault

Scleral spur identification: the AS-OCT B-scan is inspected (manually or by automated edge-detection algorithms) for the point where the inner scleral surface transitions from the corneal curvature to the flatter scleral wall — a change in slope visible as a discrete "spur" on the cross-sectional image. This point anchors every angle measurement that follows.

Angle Opening Distance (AOD500 / AOD750): the perpendicular distance from a point on the trabecular meshwork 500 µm (or 750 µm) anterior to the scleral spur, measured straight across to the anterior iris surface. It is the single most widely used AS-OCT angle metric. • Normal AOD750: roughly 0.35–0.70 mm in unselected populations • Narrow/occludable angle: AOD750 <0.19 mm is a commonly cited screening cutoff; AOD500 <200 µm is used interchangeably with an occludable Shaffer grade ≤2 in several population studies (Congdon et al.)

Trabecular-Iris Space Area (TISA750): a trapezoidal area bounded by the AOD750 line, the anterior iris surface, the scleral spur, and a line drawn perpendicular to the inner scleral wall at the scleral spur down to the iris. TISA captures both the angle width and the depth of the recess in a single area measurement (mm²), and correlates more tightly with functional trabecular meshwork exposure than AOD alone. Normal TISA750 is approximately 0.10–0.20 mm²; occludable angles are typically well under 0.10 mm².

Angle Recess Area (ARA): area bounded similarly but extended to the angle recess apex rather than a fixed 500/750 µm point — used more in research contexts to characterize overall recess morphology independent of the arbitrary anterior chamber landmark distance.

Lens vault: the perpendicular distance between the anterior pole of the crystalline lens and the horizontal line connecting the two scleral spurs (nasal and temporal). This is the parameter that most directly quantifies the phacomorphic contribution to angle crowding described in Stage 2 — elevated lens vault (>600 µm) predicts a shallower angle independent of iris configuration and predicts a smaller angle-widening response to LPI alone.

Iris curvature: quantifies the degree of anterior iris bowing (convexity) between the iris root and pupil margin — a positive, larger value indicates more pupillary-block-type bowing; a flat or even posteriorly curved iris with an abrupt peripheral roll argues for plateau configuration instead.

Pupil diameter under standardized conditions: because both illumination and accommodation dynamically change angle width, angle parameters are only clinically meaningful when the testing conditions (dark vs. light, distance fixation) are standardized and reported alongside the measurement — a dark-room AOD750 of 0.15mm and a light-room AOD750 of 0.45mm in the same eye is itself a clinically important finding, not measurement noise.

The Primary Angle-Closure Disease Spectrum — From PACS to PAC to PACG

The International Society of Geographical and Epidemiological Ophthalmology (ISGEO) classification stages angle-closure disease along a severity continuum, and AS-OCT-quantified angle narrowing is the anatomic substrate that places an eye somewhere on that continuum. Angle closure disproportionately affects East Asian populations, women, and hyperopes, making population screening — where AS-OCT's speed and non-contact nature matter enormously — a central public health application.

• ~20 million: Global angle-closure burden (people affected worldwide (Tham et al. 2014))
• ~50%: Share of glaucoma blindness (from only ~1/4 of all glaucoma cases)
• ~80–90%: East Asian share of burden (China, Vietnam, Mongolia highest prevalence)
• ~2–4:1: Female:male ratio (shallower ACD, shorter axial length)

PACS → PAC → PACG: staging definitions and why the distinction matters clinically

Primary Angle-Closure Suspect (PACS): an occludable angle — appositional iridotrabecular contact over ≥180° of the angle circumference on gonioscopy or its AS-OCT equivalent (narrow AOD/TISA) — with normal intraocular pressure, no peripheral anterior synechiae (PAS), and no glaucomatous optic neuropathy. The angle is anatomically at risk but has caused no measurable damage. This is the stage at which prophylactic intervention is debated (see Stage 6, ZAP trial).

Primary Angle Closure (PAC): an occludable angle that has caused a measurable consequence — either peripheral anterior synechiae (permanent adhesions between iris and trabecular meshwork from prior appositional contact), elevated intraocular pressure (>21 mmHg), or a history of an acute angle-closure attack — but still without glaucomatous optic nerve damage or visual field loss. PAC represents functional trabecular meshwork compromise without structural glaucoma yet.

Primary Angle-Closure Glaucoma (PACG): PAC plus glaucomatous optic neuropathy — structural optic disc changes (increased cup-to-disc ratio, rim thinning, retinal nerve fiber layer loss on OCT) with corresponding visual field defects. This is irreversible vision loss; the disease has crossed from anatomic risk into structural damage.

Progression rates: longitudinal cohorts (Thomas et al., and subsequent Asian population studies) estimate roughly 22% cumulative progression from PACS to PAC over approximately 5 years in untreated eyes, with wide variation depending on baseline angle width, family history of acute angle closure, and lens status — which is precisely the risk heterogeneity that later motivated moving away from universal prophylactic treatment (Stage 6).

Population screening implications: angle closure is markedly more prevalent in East Asian populations — accounting for an estimated 80–90% of the global disease burden — and within any population, women (2–4× the risk of men, attributable largely to a shorter axial length and shallower anterior chamber depth even after adjusting for shorter stature) and hyperopes (short axial length <23mm, thicker lens-to-eye-size ratio) are disproportionately affected. Because angle closure causes a much higher fraction of severe bilateral blindness than open-angle glaucoma relative to its prevalence — an estimated ~50% of all glaucoma blindness worldwide arises from angle closure despite representing only about a quarter of glaucoma cases overall — targeted screening of these higher-risk demographic groups using rapid, non-contact AS-OCT is a public-health priority in East and Southeast Asian eye-care systems.

Laser Peripheral Iridotomy — Nd:YAG Treatment Planning and AS-OCT Outcome Verification

Laser peripheral iridotomy remains the definitive first-line treatment for pupillary-block-mediated angle closure: a focused Nd:YAG laser burns a full-thickness opening through the peripheral iris stroma, creating a direct conduit for aqueous humor from the posterior chamber to the anterior chamber that bypasses the pupil entirely, eliminating the pressure gradient responsible for iris bowing. AS-OCT before and after the procedure provides objective, quantitative confirmation that the mechanism has actually been relieved — rather than relying on a subjective post-hoc gonioscopy impression.

• 4–8 mJ: Nd:YAG pulse energy (typical per-pulse setting)
• ≥150–200 µm: Target patency diameter (confirmed patent iridotomy)
• +0.10–0.15 mm: Mean AOD750 gain post-LPI (in eyes with pupillary-block component)
• ~30%: Plateau iris persisting post-LPI (of occludable angles need ALPI/lensectomy)

Iridotomy placement, mechanism of action, and AS-OCT-guided outcome assessment

Placement: the iridotomy is placed in the superior or superonasal iris, positioned to be covered by the upper eyelid in primary gaze. This is a deliberate choice, not convention alone — an iridotomy exposed within the palpebral fissure (temporal or inferior placement) has been associated with new monocular dysphotopsias (patient-reported arcs, lines, or crescents of light) in roughly 10% of eyes, caused by uncontrolled light entering through the second "pupil." Superior/superonasal placement under the lid margin largely avoids this.

Mechanism of pressure equalization: before LPI, aqueous produced by the ciliary body must pass through the narrow iris-lens channel to reach the anterior chamber and trabecular outflow pathway; any resistance at that channel (relative pupillary block) creates a posterior-to-anterior pressure gradient that bows the iris forward. Once the iridotomy is patent, aqueous flows directly from posterior to anterior chamber through the new opening, and the pressure gradient — and with it the anterior bowing — collapses essentially instantaneously. This is why AOD and TISA measurements typically show immediate widening on the very next AS-OCT scan.

AS-OCT outcome verification: pre-treatment AS-OCT documents baseline AOD750, TISA750, and iris curvature in both dark and light conditions. Post-LPI imaging (typically 1–4 weeks later) repeats the identical protocol. In eyes where pupillary block was the dominant or sole mechanism, mean AOD750 increases by roughly 0.10–0.15 mm and iris curvature flattens substantially — an objective, reproducible confirmation that the procedure achieved its mechanistic goal, independent of the treating surgeon's subjective impression through the slit lamp.

Persistent narrowing despite a patent iridotomy: when AS-OCT shows the angle remains appositionally narrow after a confirmed patent iridotomy (patency itself verified by visible transillumination and a clear view of the anterior lens capsule through the opening, or directly on the OCT B-scan as a full-thickness iris defect), this is diagnostic of a mechanism the iridotomy could not fix — most often plateau iris syndrome, occurring in an estimated 30% of angles that remain occludable post-LPI. Management then escalates to argon laser peripheral iridoplasty (ALPI), which applies contraction burns to the peripheral iris stroma to mechanically shrink and pull it away from the angle wall, or — particularly when AS-OCT also shows an elevated lens vault suggesting a phacomorphic contribution — to clear lens extraction, which the EAGLE trial (2016) demonstrated is more effective than iridotomy-based management alone for angle closure with elevated IOP.

The ZAP Trial and the Shift Away from Universal Prophylactic Iridotomy

For decades, the default recommendation for a patient found to have an occludable angle (PACS) on gonioscopy was prophylactic laser peripheral iridotomy in both eyes, on the reasoning that a cheap, low-risk outpatient laser procedure was clearly worth preventing a potentially blinding acute attack. The Zhongshan Angle Closure Prevention (ZAP) trial — the largest and longest randomized trial ever conducted in this space — directly tested that assumption, and its results have measurably shifted practice toward risk-stratified rather than universal treatment.

• 889 eyes: ZAP trial size (bilateral PACS, Guangzhou, China)
• 4.19%: 6-yr progression, LPI eyes (to PAC/PACG/acute attack)
• 7.11%: 6-yr progression, control eyes (observation only, fellow eye)
• ~2.9 pts: Absolute risk reduction (NNT ≈ 34 to prevent one event)

ZAP trial design, results, and the resulting move toward AS-OCT-guided risk stratification

Trial design (Jiang et al., Lancet 2019): 889 participants with bilateral PACS were enrolled in Guangzhou, China. In each participant, one eye was randomized to prophylactic Nd:YAG LPI and the fellow eye was left untreated as an observational control — an intra-patient design that controls for genetic and systemic confounders extremely well. Participants were followed for 72 months (6 years), among the longest follow-up periods of any glaucoma prevention trial.

Primary outcome: progression to PAC (development of peripheral anterior synechiae, intraocular pressure elevation >24 mmHg, or an acute angle-closure attack) or to PACG.

Results: cumulative 6-year incidence of the primary outcome was 4.19% in LPI-treated eyes versus 7.11% in observation eyes — a statistically significant but modest absolute risk reduction of roughly 2.9 percentage points, corresponding to a number needed to treat of approximately 34 eyes to prevent one progression event over six years. Acute angle-closure attacks specifically were rare in both groups (occurring in a small number of control eyes) but were essentially eliminated in the LPI-treated eyes.

Interpretation and practice change: because the great majority of PACS eyes — even untreated — did not progress over six years, and because LPI carries small but real risks (dysphotopsia, transient IOP spike, rare cases of corneal endothelial cell loss with anteriorly-positioned iridotomies), the ZAP trial results argued against reflexively treating every PACS eye with prophylactic LPI. Current practice has shifted toward risk-stratified treatment: using AS-OCT-quantified parameters (markedly narrow AOD750/TISA750, elevated lens vault, documented plateau configuration), family history of acute angle closure, high hyperopia, and shorter axial length to identify the subset of PACS patients most likely to benefit, while following lower-risk PACS eyes with periodic gonioscopy and AS-OCT rather than treating universally.

Ongoing monitoring protocol: PACS and PAC eyes are typically followed with annual (or more frequent, if risk factors are present) gonioscopy and AS-OCT to track angle parameters and detect new synechiae or IOP elevation; PACG eyes additionally require serial optic nerve head OCT and visual field testing at the same cadence used for primary open-angle glaucoma, since once glaucomatous damage is present, PACG is managed as a chronic optic neuropathy requiring the same lifelong IOP-lowering strategy and structural/functional surveillance as any other form of glaucoma.

The ZAP trial's central lesson is a statistical one as much as a clinical one: a large, real, and reproducible relative risk reduction (LPI roughly halved the six-year progression rate, 7.11% → 4.19%) can still translate into a small absolute benefit and a double-digit number needed to treat when the underlying event rate is low. That gap between relative and absolute benefit is exactly why AS-OCT-based risk stratification — concentrating prophylactic LPI on the minority of PACS eyes with the narrowest angles, highest lens vault, or strongest risk-factor profile — is now considered better medicine than treating every occludable angle the same way.